Literature DB >> 25552707

The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.

Magali Le Garff-Tavernier1, Linda Herbi2, Christophe de Romeuf3, Nabih Azar4, Damien Roos-Weil5, Patrick Bonnemye6, Rémi Urbain3, Véronique Leblond5, Hélène Merle-Beral7, Vincent Vieillard8.   

Abstract

Entities:  

Keywords:  ADCC; Waldenström macroglobulinemia; natural killer; ublituximab

Mesh：

Substances：

Year:  2014        PMID： 25552707      PMCID： PMC4380738          DOI： 10.3324/haematol.2014.118083

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies.

Authors:  M Le Garff-Tavernier; J Decocq; C de Romeuf; C Parizot; C A Dutertre; E Chapiro; F Davi; P Debré; J F Prost; J L Teillaud; H Merle-Beral; V Vieillard
Journal:  Leukemia       Date:  2010-10-26       Impact factor: 11.528

2.  Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.

Authors:  M Le Garff-Tavernier; L Herbi; C de Romeuf; F Nguyen-Khac; F Davi; A Grelier; M Boudjoghra; K Maloum; S Choquet; R Urbain; V Vieillard; H Merle-Béral
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

3.  Human NK cells display major phenotypic and functional changes over the life span.

Authors:  Magali Le Garff-Tavernier; Vivien Béziat; Julie Decocq; Virginie Siguret; Frédérique Gandjbakhch; Eric Pautas; Patrice Debré; Hélène Merle-Beral; Vincent Vieillard
Journal:  Aging Cell       Date:  2010-05-10       Impact factor: 9.304

Review 4.  Natural killer cell immune escape in acute myeloid leukemia.

Authors:  E Lion; Y Willemen; Z N Berneman; V F I Van Tendeloo; E L J Smits
Journal:  Leukemia       Date:  2012-03-26       Impact factor: 11.528

Review 5.  Targeting natural killer cells and natural killer T cells in cancer.

Authors:  Eric Vivier; Sophie Ugolini; Didier Blaise; Christian Chabannon; Laurent Brossay
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 6.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

7.  Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education.

Authors:  Niklas K Björkström; Peggy Riese; Frank Heuts; Sandra Andersson; Cyril Fauriat; Martin A Ivarsson; Andreas T Björklund; Malin Flodström-Tullberg; Jakob Michaëlsson; Martin E Rottenberg; Carlos A Guzmán; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2010-08-09       Impact factor: 22.113

8.  Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

Authors:  Christophe de Romeuf; Charles-Antoine Dutertre; Magali Le Garff-Tavernier; Nathalie Fournier; Christine Gaucher; Arnaud Glacet; Sylvie Jorieux; Nicolas Bihoreau; Christian K Behrens; Roland Béliard; Vincent Vieillard; Bruno Cazin; Dominique Bourel; Jean-François Prost; Jean-Luc Teillaud; Hélène Merle-Béral
Journal:  Br J Haematol       Date:  2008-03       Impact factor: 6.998

Review 9.  Hematological malignancies escape from NK cell innate immune surveillance: mechanisms and therapeutic implications.

Authors:  Laure Farnault; Carole Sanchez; Céline Baier; Thérèse Le Treut; Régis T Costello
Journal:  Clin Dev Immunol       Date:  2012-08-01

Review 10.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.

Authors:  Carolyn M Nielsen; Matthew J White; Martin R Goodier; Eleanor M Riley
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561
View more
  3 in total

Review 1.  Improving natural killer cell cancer immunotherapy.

Authors:  Melissa M Berrien-Elliott; Rizwan Romee; Todd A Fehniger
Journal:  Curr Opin Organ Transplant       Date:  2015-12       Impact factor: 2.640

2.  A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.

Authors:  Ahmed Sawas; Charles M Farber; Marshall T Schreeder; Mazen Y Khalil; Daruka Mahadevan; Changchun Deng; Jennifer E Amengual; Petros G Nikolinakos; Jill M Kolesar; John G Kuhn; Peter Sportelli; Hari P Miskin; Owen A O'Connor
Journal:  Br J Haematol       Date:  2017-02-21       Impact factor: 6.998

Review 3.  Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies.

Authors:  Massimo Giuliani; Alessandro Poggi
Journal:  Cells       Date:  2020-06-29       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.